Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis

ConclusionsWeight loss is common among IPF patients on antifibrotic therapy. Nintedanib therapy and more advanced disease were identified as predictors of weight loss in this population.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research